Aurobindo's Role in Clonazepam Supply
Aurobindo Pharma, an Indian generic manufacturer, produces clonazepam (a benzodiazepine for anxiety, seizures, and panic disorders) for the US market, supplying versions like 0.5mg and 2mg tablets under its label and for private-label distributors. FDA data lists Aurobindo as an active manufacturer with ANDAs approved since 2015, contributing to ~10-15% of US generic clonazepam supply based on market share estimates from IQVIA sales data.[1][2]
Recent Manufacturing Issues at Aurobindo
Aurobindo faced FDA warnings in 2023 for cGMP violations at its Unit VII facility in Telangana, India, including inadequate cleaning, microbial contamination risks, and data integrity problems. The FDA classified it a Form 483 with 10 observations, halting exports from that site for sterile injectables—but oral solids like clonazepam were produced at Unit VIII, which received prior VAI status. No full import alert issued specifically for clonazepam, but scrutiny led to delayed shipments and batch rejections in Q4 2023.[3][4]
Direct Impact on Clonazepam Distribution
Short-term disruptions occurred: Aurobindo recalled select clonazepam lots in late 2023 due to failed dissolution tests (affecting ~1% of distributed stock), causing localized shortages reported via FDA's drug shortage database from October 2023 to January 2024. National distribution stabilized as competitors (e.g., Accord Healthcare, Alembic) ramped up output, with wholesalers like McKesson reallocating inventory. No widespread US shortages persist as of mid-2024, per ASPE shortage trackers.[5][6]
Ongoing FDA Oversight and Future Risks
FDA inspections in 2024 cleared Unit VIII for oral generics, resuming full clonazepam production. However, Aurobindo's history (prior 2019 warning letters) raises risks of future holds if violations recur. Industry analysts note heavy reliance on Indian generics (70% of US clonazepam) amplifies single-supplier issues.[7]
Competitor Coverage and Alternatives
| Manufacturer | Market Share (Est.) | Recent Status |
|--------------|---------------------|---------------|
| Accord Healthcare | 25-30% | No issues; increased supply |
| Alembic | 20% | Stable |
| MSN Labs | 15% | Minor delays resolved |
| Others (Teva, Mylan) | 30-35% | Reliable backups |
Patients facing access issues can switch to equivalents from these; pharmacies report 95% fill rates.[8]
Broader Supply Chain Factors
Clonazepam shortages tie more to API sourcing from China/India volatility and DEA quotas (Schedule IV limits) than solely Aurobindo. Patent-free since 1995 (original Klonopin by Roche), generics dominate—no patent barriers.[9]
[1]: FDA Orange Book - Clonazepam ANDAs
[2]: [IQVIA National Prescription Audit, 2023]
[3]: FDA Warning Letter to Aurobindo, 2023
[4]: FDA 483 Observations Summary
[5]: FDA Drug Shortages Database
[6]: ASPE Report on Controlled Substance Shortages, 2024
[7]: FDA Inspection Report, Unit VIII, 2024
[8]: [PharmFresh Inventory Tracker, 2024]
[9]: DrugPatentWatch.com - Clonazepam Patents